Clinical response at 10 weeks · people with active UC
Cannabidiol showed no clear difference in clinical response at 10 weeks compared with placebo (low certainty).
1 finding from 1 review
CRP (mg/dL) at end of study · people with active UC
1 finding from 1 review
IBDQ at week 6 · people with active UC
1 finding from 1 review
Adverse events · people with active UC
Cannabidiol probably leads to higher adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with active UC
Cannabidiol showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with active UC
Cannabidiol showed no clear difference in withdrawal due to adverse event compared with placebo (low certainty).
1 finding from 1 review
Clinical remission · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical response · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · adults and paediatric patients with dermal laceration
5 findings from 1 review
no estimate extracted
6 studies · 1006 participants
Low
no estimate extracted
4 studies · 530 participants
Low
no estimate extracted
6 studies · 543 participants
Low
Show 2 more findings
Anaesthetic‐related adverse effects · adults and paediatric patients with dermal laceration
Primary outcome: topical local anaesthetics led to lower anaesthetic‐related adverse effects compared with infiltrated local anaesthetics or other topical agents; GRADE not reported.
1 finding from 1 review
Intervention not reported
Participant self‐reported VAS (0‐100 mm) pain scores · treatment repair of dermal laceration
1 finding from 1 review
Failure to maintain remission · Patients with quiescent ulcerative colitis
Azathioprine may leads to lower failure to maintain remission compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Acute pancreatitis · Patients with quiescent ulcerative colitis
It is very uncertain whether the intervention changes acute pancreatitis (very low certainty).
1 finding from 1 review
Intervention not reported
Bone marrow suppression · Patients with quiescent ulcerative colitis
It is very uncertain whether the intervention changes bone marrow suppression (very low certainty).
1 finding from 1 review
Any adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether azathioprine changes any adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether azathioprine changes withdrawal due to adverse event compared with placebo (very low certainty).
1 finding from 1 review
Failure to maintain remission · Patients with quiescent ulcerative colitis
It is very uncertain whether azathioprine changes failure to maintain remission compared with sulfasalazine (very low certainty).
1 finding from 1 review
Failure to maintain remission · Patients with quiescent ulcerative colitis
It is very uncertain whether 6‐Mercaptopurine changes failure to maintain remission compared with 5‐ASA (very low certainty).
1 finding from 1 review
Failure to maintain remission · Patients with quiescent ulcerative colitis
It is very uncertain whether 6‐Mercaptopurine changes failure to maintain remission compared with methotrexate (very low certainty).
1 finding from 1 review
Failure to maintain remission · Patients with quiescent ulcerative colitis
It is very uncertain whether azathioprine (AZA) changes failure to maintain remission compared with cyclosporin of remission (very low certainty).
1 finding from 1 review